Shin Nippon Biomedical Laboratories, Ltd.

Informe acción TSE:2395

Capitalización de mercado: JP¥62.3b

Shin Nippon Biomedical Laboratories Dirección

Dirección controles de criterios 2/4

El CEO de Shin Nippon Biomedical Laboratories es Ryoichi Nagata, nombrado en Jan 1991, tiene una permanencia de 33.83 años. posee directamente un 2.46% de las acciones de la empresa, con un valor de ¥1.53B. La antigüedad media del equipo directivo y de la junta directiva es de 2.4 años y 9.4 años, respectivamente.

Información clave

Ryoichi Nagata

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEOn/a
Permanencia del CEO33.8yrs
Participación del CEO2.5%
Permanencia media de la dirección2.4yrs
Promedio de permanencia en la Junta Directiva9.4yrs

Actualizaciones recientes de la dirección

Recent updates

Shin Nippon Biomedical Laboratories' (TSE:2395) Dividend Will Be ¥20.00

Sep 19
Shin Nippon Biomedical Laboratories' (TSE:2395) Dividend Will Be ¥20.00

Earnings Miss: Shin Nippon Biomedical Laboratories, Ltd. Missed EPS By 88% And Analysts Are Revising Their Forecasts

Aug 09
Earnings Miss: Shin Nippon Biomedical Laboratories, Ltd. Missed EPS By 88% And Analysts Are Revising Their Forecasts

Little Excitement Around Shin Nippon Biomedical Laboratories, Ltd.'s (TSE:2395) Earnings As Shares Take 28% Pounding

Aug 06
Little Excitement Around Shin Nippon Biomedical Laboratories, Ltd.'s (TSE:2395) Earnings As Shares Take 28% Pounding

Shin Nippon Biomedical Laboratories' (TSE:2395) Dividend Will Be ¥20.00

Jul 26
Shin Nippon Biomedical Laboratories' (TSE:2395) Dividend Will Be ¥20.00

Shin Nippon Biomedical Laboratories' (TSE:2395) Dividend Will Be ¥20.00

Jul 12
Shin Nippon Biomedical Laboratories' (TSE:2395) Dividend Will Be ¥20.00

Shin Nippon Biomedical Laboratories' (TSE:2395) Sluggish Earnings Might Be Just The Beginning Of Its Problems

May 21
Shin Nippon Biomedical Laboratories' (TSE:2395) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Shin Nippon Biomedical Laboratories, Ltd. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

May 10
Shin Nippon Biomedical Laboratories, Ltd. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Shin Nippon Biomedical Laboratories (TSE:2395) Is Due To Pay A Dividend Of ¥30.00

Mar 12
Shin Nippon Biomedical Laboratories (TSE:2395) Is Due To Pay A Dividend Of ¥30.00

Shin Nippon Biomedical Laboratories (TSE:2395) Has Affirmed Its Dividend Of ¥30.00

Feb 27
Shin Nippon Biomedical Laboratories (TSE:2395) Has Affirmed Its Dividend Of ¥30.00

CEO

Ryoichi Nagata (66 yo)

33.8yrs

Permanencia

JP¥144,061,000

Compensación

Dr. Ryoichi Nagata, M.D., Ph D., F.F.P.M., serves as President & Director of Satsuma Pharmaceuticals, Inc. since June 8, 2023 Also serves as it's Chief Executive Officer and Group Financial Officer since 2...


Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Ryoichi Nagata
President33.8yrsJP¥144.06m2.46%
¥ 1.5b
Fumihiko Makino
Senior Executive Officer2.8yrssin datossin datos
Toshiyuki Iwata
Managing Executive Officerno datasin datossin datos
Shinji Nitanda
Senior MD of Corporate Development & Corporate Tax Administration and Director2.4yrssin datossin datos
Kyomi Nagatoshi
Senior Managing Executive Officerno datasin datossin datos
Ken Takanashi
Executive VP of Group Corporate Management & Global Business & Director20.4yrssin datos0.090%
¥ 56.0m
Satoshi Matsumoto
Managing Executive Officer & GM of Fisheries Divisionless than a yearsin datossin datos
Hideshi Tsusaki
Senior MD1.8yrssin datossin datos
Terumasa Hirai
Managing Executive Officer & President and Representative Director of SNBL Ina Research Centerno datasin datossin datos
Shu-Ichi Kanazashi
Managing Executive Officerless than a yearsin datossin datos
Eishi Tsunozaki
Senior MD & Directorno datasin datos0.043%
¥ 27.1m
Ichiro Nagata
Executive VPno datasin datos40.32%
¥ 25.1b

2.4yrs

Permanencia media

57yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 2395 se considera experimentado (2.4 años antigüedad media).


Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Ryoichi Nagata
President41.6yrsJP¥144.06m2.46%
¥ 1.5b
Shinji Nitanda
Senior MD of Corporate Development & Corporate Tax Administration and Director14.4yrssin datossin datos
Kyomi Nagatoshi
Senior Managing Executive Officerno datasin datossin datos
Ken Takanashi
Executive VP of Group Corporate Management & Global Business & Director21.9yrssin datos0.090%
¥ 56.0m
Hideshi Tsusaki
Senior MD10.4yrssin datossin datos
Eishi Tsunozaki
Senior MD & Director10.4yrssin datos0.043%
¥ 27.1m
Ichiro Nagata
Executive VP4.4yrssin datos40.32%
¥ 25.1b
Shinichi Fukumoto
Independent Outside Director9.4yrssin datos0.00096%
¥ 598.3k
Takashi Yamashita
Independent Outside Director9.4yrssin datos0.00096%
¥ 598.3k
Tsuyoshi Hanada
Independent Outside Director4.4yrssin datos0.0098%
¥ 6.1m
Keiko Totani
Independent Outside Director3.4yrssin datos0.0019%
¥ 1.2m
Chizuru Horishita
Independent Outside Directorless than a yearsin datossin datos

9.4yrs

Permanencia media

60yo

Promedio de edad

Junta con experiencia: La junta directiva de 2395 se considera experimentada (9.4 años de antigüedad promedio).